# Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/hypertension-indication-drug-labeling-for-cardiovascular-outcome-claims/79efdd86-3643-466c-8fe3-82b6ad2e95ff

> FDA guidance document: Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims. Issue date: March 15, 2011. Get complete insights and analysis.

---

## Details

- Title: Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2011-03-15
- Last Changed: 2023-01-12
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2008-D-0150">FDA-2008-D-0150</a>

## Related Documents

- [Expedited Programs for Serious Conditions | Drugs and Biologics](https://www.globalkeysolutions.net/guidances/guidance-document/expedited-programs-for-serious-conditions-drugs-and-biologics/d49c172d-43db-4e76-a0fd-1f51de9ecff3)
- [Pre-Launch Activities Importation Requests (PLAIR):  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/pre-launch-activities-importation-requests-plair-guidance-for-industry/66c1d94d-25c8-49ce-a669-977492f04bbf)
- [CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports](https://www.globalkeysolutions.net/guidances/guidance-document/cmc-postapproval-manufacturing-changes-to-be-documented-in-annual-reports/67341cfe-8a48-4fc7-9817-6f9ed89768cf)